Studieprotocol
Download
Flowchart
Follow-up schema
| Inclusie | Dag 1 | Week 2 | Week 4 | Week 8 | Week 12 | Maand 6 | |
|---|---|---|---|---|---|---|---|
| Baseline | |||||||
| In- en exclusiecriteria | X | ||||||
| Baseline gegevens | X | ||||||
| Behandeling | |||||||
| TXA of placebo | X | X | X | ||||
| Primaire uitkomstmaat | |||||||
| 1. Operatie voor cSDH? | X | X | X | X | X | ||
| Secundaire uitkomstmaten | |||||||
| 2. cSDH volume | X | X | X | X | |||
| 3. mNIHSS | X | X | X | X | |||
| 4. Valincidenten | X | X | X | X | |||
| 5. MOCA | X | X | X | X | |||
| 6a. Barthel | X | X | X | ||||
| 6b. Lawton-Brody | X | X | X | ||||
| 7. mRS | X | X | X | ||||
| 8a. SF-36 | X | X | X | ||||
| 8b. EQ-5D | X | X | X | ||||
| 9. Mortaliteit | X | X | X | X | |||
| 10a. iMCQ | X | X | X | X | |||
| 10b. iPCQ | X | X | X | X | |||
| Overig | |||||||
| Evaluatie wilsbekwaamheid | X | X | X | X | X | ||
| (S)AE's | X | X | X | X | X | ||
Inclusies
0
554
AMC: 178,
VUmc: 5,
MUMC: 20,
Tergooi: 7,
NWZ: 15,
Isala: 16,
vWeel Bethesda: 1,
Zuyderland: 10,
HMC: 1,
Radboud: 6,
MST: 1,
Gelre: 2
Update: 20 Nov 2024
Contact
Financiers
Deelnemende centra
